{
    "nct_id": "NCT06608927",
    "official_title": "A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma",
    "inclusion_criteria": "* Have histologically or cytologically confirmed PDAC that is metastatic.\n* Have not been previously treated for PDAC in the metastatic setting.\n\n  1. Prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed at least 12 months before randomization.\n  2. Prior palliative radiotherapy is allowed if completed at least 2 weeks prior to randomization and AEs have resolved to Grade 1 or less before randomization.\n  3. Prior and/or placement of a biliary stent/tube is permitted if any treatment-related AEs have improved to Grade â‰¤ 1 and the patient is not exhibiting any signs/symptoms of biliary obstruction.\n* Eastern Cooperative Oncology Group PS of 0 to 1.\n* At least 1 target lesion measurable by computed tomography (CT)/magnetic resonance imaging (MRI) per RECIST v1.1. not within a field of prior radiation therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previously treated for locally advanced, unresectable PDAC.\n* History of brain metastases or leptomeningeal metastases.\n* Prior treatment with a CD73 antagonist or inhibitor.\n* Underlying medical conditions that, in the investigator or sponsor's opinion, will make the administration of study-specified therapy hazardous\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}